drug marketdrug utilizationWe examined the success of product line extensions (PLEs) in Canada by studying five selected drugs, three with generic competitors (ciprofloxacin, fenofibrate, paroxetine) and two without (clarithromycin, tolterodine). Third-party prescription claims from Canada were used to...
genericcompetitiondrug marketdrug utilizationABSTRACT We examined the success of product line extensions (PLEs) in Canada by studying five selected drugs, three with generic competitors (ciprofloxacin, fenofibrate, paroxetine) and two without (clarithromycin, tolterodine). Third-party prescription claims ...